Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide

      The purpose of this study was to develop a new monolithic matrix tablet to completely deliver glipizide in a zero order manner over a sustained period. Two approaches were examined using drug in a formulation that contain polymer like hydroxylpropyl methyl-cellulose K 100 (HPMCK) and Eudragit L 100. The granules were prepared by wet granulation method and thereby formulated as F-1, F-2. F-3 and F-4 by using the above bring up polymers with other ingredients. The granules of different formulations were evaluated for angle of repose, loose bulk density and tapped density, compressibility index, total porosity, and drug content. The angle of repose and compressibility index (%) ranged from 25.0±0.8 to 28.0±1.1 and 12.92±0.02 to 13.08±0.03, respectively. The results of angle of repose (in vitro drug release was measured by means of dissolution apparatus. Of the various formulation distinguished, out of which, the formulation (F3) were preferred to be full of 30 mg of HPMCK and 35 mg of Eudragit L100 was subjected to stability were accomplished studies for three months at 4 °C. The room temperature (25 °C) and (45 °C) with relative humidity 75±5% were maintained and its stability with respect to release pattern. The kinetic release treatment showed that the release of drug follows zero order kinetic (r2= 0. 9959), Koresmeyer equation gave value of r2= 0.9853 which was close to one indicating that the drug was released by zero order kinetic. According to Koresmeyer equation, the formulation F-1, F-2, and F-4 showed the regression values of 0.9823, 0.9785, and 0.9742, respectively. The identical plot for (log cumulative percentage drug release vs time) for Koresmeyer-Peppas equation indicated a good linearity for the commercially available sustained release tablet and formulation F-3 with regression values of 0.9619 and 0.9959, respectively. Scanning electron microscope confirmed both diffusion and erosion mechanism for the optimized batch of matrix tablet F-3. Results suggest that the formulated tablet F-3 of glipizide could perform therapeuti-cally better than the reachable marketed drug leading to improve better efficacy.